Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SETD5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SETD5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SETD5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SETD5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SETD5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SETD5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SETD5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SETD5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SETD5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SETD5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00349687 | Oral cavity | OSCC | histone lysine methylation | 58/7305 | 115/18723 | 8.25e-03 | 3.01e-02 | 58 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
GO:003105622 | Oral cavity | EOLP | regulation of histone modification | 38/2218 | 152/18723 | 5.18e-06 | 1.05e-04 | 38 |
GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
GO:004354321 | Oral cavity | EOLP | protein acylation | 51/2218 | 243/18723 | 3.11e-05 | 4.41e-04 | 51 |
GO:000647321 | Oral cavity | EOLP | protein acetylation | 44/2218 | 201/18723 | 3.69e-05 | 5.12e-04 | 44 |
GO:003432917 | Oral cavity | EOLP | cell junction assembly | 76/2218 | 420/18723 | 1.02e-04 | 1.17e-03 | 76 |
GO:001839421 | Oral cavity | EOLP | peptidyl-lysine acetylation | 37/2218 | 169/18723 | 1.48e-04 | 1.58e-03 | 37 |
GO:190198321 | Oral cavity | EOLP | regulation of protein acetylation | 21/2218 | 77/18723 | 1.74e-04 | 1.80e-03 | 21 |
GO:001839321 | Oral cavity | EOLP | internal peptidyl-lysine acetylation | 34/2218 | 158/18723 | 3.76e-04 | 3.40e-03 | 34 |
GO:001657321 | Oral cavity | EOLP | histone acetylation | 33/2218 | 152/18723 | 3.85e-04 | 3.46e-03 | 33 |
GO:000647521 | Oral cavity | EOLP | internal protein amino acid acetylation | 34/2218 | 160/18723 | 4.79e-04 | 4.19e-03 | 34 |
GO:200075621 | Oral cavity | EOLP | regulation of peptidyl-lysine acetylation | 17/2218 | 63/18723 | 8.00e-04 | 6.31e-03 | 17 |
GO:003496813 | Oral cavity | EOLP | histone lysine methylation | 26/2218 | 115/18723 | 8.11e-04 | 6.35e-03 | 26 |
GO:001657113 | Oral cavity | EOLP | histone methylation | 30/2218 | 141/18723 | 9.78e-04 | 7.39e-03 | 30 |
GO:19018889 | Oral cavity | EOLP | regulation of cell junction assembly | 39/2218 | 204/18723 | 1.67e-03 | 1.11e-02 | 39 |
GO:000647913 | Oral cavity | EOLP | protein methylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:000821313 | Oral cavity | EOLP | protein alkylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:003506511 | Oral cavity | EOLP | regulation of histone acetylation | 14/2218 | 54/18723 | 3.37e-03 | 1.94e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SETD5 | SNV | Missense_Mutation | novel | c.572N>G | p.Ser191Cys | p.S191C | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SETD5 | SNV | Missense_Mutation | | c.1130N>T | p.Ser377Phe | p.S377F | Q9C0A6 | protein_coding | deleterious(0.01) | possibly_damaging(0.596) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SETD5 | SNV | Missense_Mutation | | c.1853N>A | p.Arg618Gln | p.R618Q | Q9C0A6 | protein_coding | tolerated(0.07) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SETD5 | SNV | Missense_Mutation | novel | c.2798N>T | p.Arg933Ile | p.R933I | Q9C0A6 | protein_coding | tolerated(0.05) | benign(0.202) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SETD5 | SNV | Missense_Mutation | | c.2936N>T | p.Thr979Ile | p.T979I | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SETD5 | SNV | Missense_Mutation | | c.1079N>A | p.Val360Glu | p.V360E | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
SETD5 | SNV | Missense_Mutation | novel | c.4180N>C | p.Ala1394Pro | p.A1394P | Q9C0A6 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SETD5 | SNV | Missense_Mutation | | c.2198C>A | p.Ala733Glu | p.A733E | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
SETD5 | SNV | Missense_Mutation | | c.3980C>G | p.Ser1327Cys | p.S1327C | Q9C0A6 | protein_coding | deleterious(0) | benign(0.001) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
SETD5 | SNV | Missense_Mutation | | c.2377N>G | p.Met793Val | p.M793V | Q9C0A6 | protein_coding | tolerated(0.23) | benign(0.16) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |